47
BioTOPics 46 | September 2013
BioTOP-Report
ProBioGen AG
ProBioGen AG is an internationally operating
Contract Development & Manufacturing
Organization (CDMO) and Technology Pro-
vider, focused on animal cell line engineer-
ing and process development including GMP
manufacturing of biopharmaceutical drug
substances (therapeutic proteins and vac-
cines).
Almost 20 years of experience in mammali-
an cell culture and biopharmaceutical manu-
facturing make ProBioGen a competent and
reliable contract partner. The comprehensive
technological skills and the outstanding sci-
entific excellence, reflected in a strong intel-
lectual property base, qualify ProBioGen to
manage even the most challenging develop-
ment and manufacturing projects.
The pharmaceutical cell line development
program is based on proprietary expression
vector technology, optimized clone selection
and screening workflow complemented by
an in-house chemically defined cell culture
media platform. Two preselected CHO host
cell lines (DG44- and K1-strains for optimal
product quality) fit perfectly into the rapid
upscale processes and achieve excellent
product yields and stability. Comprehensive
analytical methods development and valida-
tion goes hand in hand with state-of-the-art
GMP manufacturing programs.
All services and technologies are embedded
in a total quality management system to
assure compliance with international ISO
and GMP standards (EMA/FDA).
An experienced project management
ensures that projects are completed strictly
in time and on budget.
Besides the state-of-the-art services, ProBio-
Gen develops innovative technologies, such
as:
k
GlymaxX
®
This fucose-targeted glyco-engineering
technology increases the binding of
antibodies to NK cells and thus enhances
ADCC. As a permanent modification it
can be rapidly applied to any existing
antibody producer cell lines or to entire
expression platforms.
k
Pathway Modulator Technology
This permanent cell modification increas-
es productivity even for difficult to
express proteins. It is applicable to new
and pre-existing producer cell lines.
k
AGE1 Designer Cell Lines
The AGE1 cell line family was created by
defined immortalization of primary cells
for different purposes.
k
The AGE1.CR
®
cell line originates from
the Muscovy Duck and was established
to replace primary chicken cells in vac-
cine production. The cell line allows
GMP-complaint production of a wide
spectrum of vaccines and viral vectors.
k
The AGE1.HN
®
human neuronal cell line
supports complex specific glycostruc-
tures (highly sialylated, highly branched).
It is used for glycoproteins which require
manufacturing in human cells.
k
Human Artificial Lymph Node
(huALN)
The huALN is a fully human mini-
bioreactor system to assay drug-related
effects on the immune system in vitro.
This unique 3-D matrix-based technology
uses primary lymphocytes to emulate in
vivo conditions of the human immune
system and allows long-term analyses of
immunogenicity, immunofunction and
immunotoxicity.
Founded in 1994, ProBioGen is located in
Berlin, Germany, and enjoys a global cus-
tomer portfolio ranging from small biotech
firms to large pharmaceutical companies.
Address
ProBioGen AG
Goethestraße 54
13086 Berlin · Germany
Contact
Dr. Gabriele Schneider
VP Business Development
Phone +49 30 924 006 0
Fax
+49 30 924 006 149
cmo@probiogen.de
www.probiogen.de
48
BioTOPics 46 | September 2013
BioTOP-Report
syneed medidata GmbH
Are you getting the whole picture?
We Do.
syneed medidata GmbH is an independent,
privately owned contract research organiza-
tion (CRO) that has been providing end-to-
end services for phase I to phase IV clinical
trials and for observational studies for more
than 25 years. Since 1995, we have also
excelled in trials with medical devices, and
in trials involving medical imaging, including
all responsibilities of an Imaging Core Lab
(ICL). With our exceptionally low staff turn-
over, project teams usually remain stable,
even throughout multi-year projects, and as
such facilitate project delivery in time and
highest quality.
syneed medidata GmbH combines experi-
ence with the quality, dedication and
flexibility of a midsized organization. Our
proprietary EDC system, tailor-made for
multinational observational studies, gets
enthusiastic feedback from both customers
and end-users. Its advantages are, among
others, unlimited flexibility in study design
and multilingualism, compatibility with iPad
and Android tablets, and an attractive price/
performance ratio.
So, for almost any trial you can think of, we
provide the expertise you need for turning
data into results.
Address
syneed medidata GmbH
Cicerostraße 21
10709 Berlin · Germany
Phone +49 30 31172751 00
www.medidata.de
info@medidata.de
Contact
Dr. Achim Zinggrebe
CEO
Medical Director Imaging
achim.zinggrebe@medidata.de
syneed imaging
syneed imaging, the Medical Imaging Core
Lab of syneed medidata GmbH, offers solu-
tions for study planning, protocol develop-
ment, site evaluation, image collection and
processing and conduct of central indepen-
dent reviews with a wide variety of criteria
(i.e. RECIST, 1.0 and 1.1, Choi, Cheson, irRC,
RANO, PERCIST, mRECIST).
Since 1995, we have managed trials involv-
ing medical imaging (oncology, neurology,
radiology, devices) and conducted central
reads in our offices in Constance and Berlin
as well as remotely. Our experience, flexibil-
ity and pricing especially for early phase tri-
als are highly valued by Biotech clients. All
study data are hosted solely in Germany on
our servers maintained by own IT staff.
Address
syneed imaging & syneed medidata GmbH
Cicerostraße 21
10709 Berlin · Germany
Phone +49 30 31172751 00
Contact
Isabel Kloer
MD
Medical Director Imaging
isabel.kloer@medidata.de
Full-service for clinical trials
Proprietary EDC system
Very high staff retention
Tailor-made services instead of
one-size-fits-all approaches
High experience of staff
High quality delivered while being
reasonably priced